Tag Archives: ODD

December, 2017

November, 2017

October, 2017

September, 2017

  • 22 September

    FDA Grants Orphan Drug Designation to PhaseRx’s Rare Liver Disease Drug

    SEATTLE, Sept. 20, 2017 /PRNewswire/ — PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its second drug development candidate, PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), has received orphan drug designation by the U.S. Food and …

August, 2017

July, 2017